Bright Minds Biosciences Stock Beta
| DRUG Stock | USD 35.33 2.95 9.11% |
Bright Minds Biosciences fundamentals help investors to digest information that contributes to Bright Minds' financial success or failures. It also enables traders to predict the movement of Bright Stock. The fundamental analysis module provides a way to measure Bright Minds' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bright Minds stock.
Bright | Beta |
Bright Minds Biosciences Company Beta Analysis
Bright Minds' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Bright Minds Beta | 1.13 |
Most of Bright Minds' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bright Minds Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bright Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Bright Minds is extremely important. It helps to project a fair market value of Bright Stock properly, considering its historical fundamentals such as Beta. Since Bright Minds' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bright Minds' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bright Minds' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Bright Minds Biosciences has a Beta of 1.132. This is 31.63% higher than that of the Biotechnology sector and 18.56% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Bright Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bright Minds' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bright Minds could also be used in its relative valuation, which is a method of valuing Bright Minds by comparing valuation metrics of similar companies.Bright Minds is currently under evaluation in beta category among its peers.
Bright Minds ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bright Minds' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bright Minds' managers, analysts, and investors.Environmental | Governance | Social |
Bright Minds Institutional Holders
Institutional Holdings refers to the ownership stake in Bright Minds that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bright Minds' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bright Minds' value.| Shares | Advisorshares Investments, Llc | 2024-09-30 | 182.4 K | Jane Street Group Llc | 2024-06-30 | 10.9 K | Royal Bank Of Canada | 2024-06-30 | 510 | Aspire Private Capital, Llc | 2024-09-30 | 100.0 | Blackrock Inc | 2024-06-30 | 1.0 |
Bright Minds returns are very sensitive to returns on the market. As the market goes up or down, Bright Minds is expected to follow.
Bright Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 242.02 M | ||||
| Shares Outstanding | 6.08 M | ||||
| Shares Owned By Insiders | 27.28 % | ||||
| Shares Owned By Institutions | 44.27 % | ||||
| Number Of Shares Shorted | 322.61 K | ||||
| Price To Book | 56.48 X | ||||
| EBITDA | (7.28 M) | ||||
| Net Income | (7.37 M) | ||||
| Cash And Equivalents | 8.64 M | ||||
| Cash Per Share | 0.71 X | ||||
| Total Debt | 73.55 K | ||||
| Current Ratio | 22.88 X | ||||
| Book Value Per Share | 1.37 X | ||||
| Cash Flow From Operations | (7.02 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (0.63) X | ||||
| Target Price | 4.87 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 246.44 M | ||||
| Total Asset | 6.88 M | ||||
| Retained Earnings | (31.55 M) | ||||
| Working Capital | 6.53 M | ||||
| Net Asset | 6.88 M |
About Bright Minds Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bright Minds Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bright Minds using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bright Minds Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:Check out Bright Minds Piotroski F Score and Bright Minds Altman Z Score analysis. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.